Investing in Prevention Makes Good Financial Sense
Primary prevention is relatively inexpensive compared to the costs of addiction
Nora's Blog
In Memoriam—Herbert Kleber
|
With the passing of Herbert Kleber on October 5, the field of addiction research has lost a true giant—one of its biggest thinkers as well as one of the most...
3 Comments
|
Medication is a crucial part of treating addiction—but by itself, a pill or an injection may not be sufficient. Social support has long been known to be an important factor...
|
Nicotine does not produce the kind of euphoria or impairment that many other drugs like opioids and marijuana do. People do not get high from smoking cigarettes or vaping. Yet...
|
The public health emergency of opioid misuse and addiction affects millions of Americans and requires innovative scientific solutions. Today, during “National Prescription Opioid and Heroin Awareness Week,” we are sharing...
|
Ample evidence shows methadone and buprenorphine reduce overdose deaths, prevent the spread of diseases like HIV, and enable people to take back their lives, but there are restrictions on who...
|
Reducing healthcare’s reliance on potentially addictive opioid pain relievers has been one of the pillars of federal efforts to reverse the opioid crisis.
|
This week, the Food and Drug Administration (FDA) approved Epidiolex (cannabidiol, or CBD), a medication extracted from marijuana, for the treatment of two severe pediatric seizure disorders.
|
In spring 2018, Congress added an additional $500 million to the NIH budget to invest in science to find solutions to the opioid crisis. The funding that NIDA is receiving...
|
This week, the Food and Drug Administration (FDA) approved lofexidine, the first medication targeted specifically to treat the physical symptoms associated with opioid withdrawal.
|
New data-gathering and analytic capabilities are enabling the kinds of massive, long-term studies needed to investigate genetic, environmental, and lifestyle factors that contribute to disease.